Generex Biotechnology Cp Del Com (NASDAQOTCBB:GNBT)

Last ditch pump........

We're Only Giving You Winners!

Do your home work and always make sure you speak with your registered advisor before you make any decision.

Who Is Dr. Craig Eagle?

www.shamrockstocks.com

Generex Oncology Names Dr. Craig Eagle to its Scientific Advisory Board to Assist with its Proprietary Cancer Vaccines Program

Recently, Generex Biotechnology Corporation (Nasdaq: GNBT ) (www.generex.com) announced that it has named Craig Eagle, M.D. to its scientific advisory board. Dr. Eagle brings a wealth of oncology experience to help the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), dba "Generex Oncology", further its synthetic cancer and influenza vaccine development efforts.

Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.

Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney.

He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training he performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group.

In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.

In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the world wide lead for development of celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for irinotecan and dalteparin.

In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.

"We are very pleased to add Dr. Eagle to our team of scientific advisors," stated Anna Gluskin, the Company's President & Chief Executive Officer. "His wealth of experience in oncology and drug development will be invaluable as we work to advance our vaccine technologies at Antigen Express.

Additionally, his hands-on experience in strategic alliances and partnerships will provide us with additional guidance as we seek to commercialize these platforms in the future."

Commenting on his decision to join the scientific advisory board of Generex, Dr. Eagle stated: "I am very excited to be a part of the important advancements in cancer vaccine technologies being made at Generex Oncology. I look forward to advising the Company in its future oncology development efforts and helping Generex to navigate this important platform through its remaining trials and on to eventual commercialization."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, buccal insulin (Generex Oral-lyn(TM), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic s for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

We ask you to stay focused on Nasdaq:GNBT! This company keeps making the right moves!

The ShamrockstocksTeam

http://shamrockstocks.com/disclaimer.html

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

GNBT's Oral insulin delivery system is a significant advancement in the treatment of Diabetes Mellitus and will be soon approved for use in the USA. It will be a cash cow, funding the companies cancer treatment programs for the foreseeable future.

I expect GNBT to be a blockbuster stock.

jpg101 @5.53

Good potential. desired remedy. easy medication control for diabetes & others.

GNBT is one of the few companies that is making insulin that is deliverable by the oral route, the advantages of generex's product is that it's delivered via the mucous membrane of the mouth,rather then inhaled and absorbed by the lung as other oral insulin makers, the latter deliver method has a number of disadvantages including variable absorption and problems in patients with lung disease.
generex also holds a number of patents based on antigen treatment via mucous membrane absorption to treat a variety of infectious or carcinomatous diseases- these are in the development phase, if successful the company would have significant gains.
this companies insulin product hasn't been approved in the US yet- it has been approved in ecuador and recently in india-

I have owned stock in the company for about a year now and have watched it rise big and then fall big. They have a new delivery method for drugs through an inhaler that I think will be a big hit though.

Stock has gained first large country approval (India) for Oralynn and should gain approvals in Canada and then USA not long after.Wall Street has just begun to notice this company with three firms setting price targets ranging from $5.50 to $7.00.Not bad for a stock currently trading under $2.00 to be recieved that way on Wall Street.

Rates of diabetes will continue to climb. This company is developing a spray insulin delivery system. After they get FDA approval in the US, this stock should go up.

Ora-Lyn will come to market

Oral insulin.

Definitley a up and comer with Phase III trials beginning soon, several pipeline revenue streams currently active in third world countries and the cancer/avian bird flu vaccine work, they are also a likely target for takeover by a big firm.

Will concede the point on trying to bypass FDA testing reg's though, I've heard that about them in the past, hopefully Phase III will put that issue to rest as this company could easily be a groundbreaker.

is this up an coming

Still a very small developmental drug company. Has now moved into Phase III trials and if approved, revenues could drive stock price high.

interesting pipeline

their oral diabetes drug could be big

Hey, I;m out with my family or friends, and I need to stick a needle in my arm to get my insulin or turn my head, and breath my asthma pump like spray. This is a no brainer. This will go with world wide appeal, and grow like a supernova. BUY. BUY. BUY. and when your done buy some more.

the molecular process works, now they need to stick something in the machine and sell it. When they start getting revenue, this one will explode.

Okay. R&R just put out a 6 PT on this. If you like this company, you will really like micro-cap, NVD, with a much broader patent protection on its oral spray technology. Rumors have NVD working with Phizer on oral viagra. They have NDA filing for Zolpidem which should get a partnership this year.

Okay. Please excuse the shameless NVD pump. I just think its greatly undervalued considering this company is worth twice as much.